in-vitro-antimicrobial-activity-of-acne-drugs-against-skin-associated-bacteria

Views: 0

Introduction

Acne vulgaris is a common skin disease1 that affects almost all teenagers and many adults to a degree. It is estimated as the eighth most prevalent global disease, with 650 million people reported to have had acne in 20102. The development of acne proceeds in four stages, starting with excess sebum production and modified lipid composition in the sebaceous gland at the base of hair follicles, which is followed by blocking of the skin pore, then colonization by Propionibacterium acnes (recently renamed as Cutibacterium acnes, but with the original designation still favored in the dermatological community3), which induces inflammation and pustule formation1,4,5. Treatment options include skin cleansing to remove excess oil and unblock pores, skin abrasives (including chemical peeling agents such as benzoyl peroxide 1, azelaic acid 2, salicyclic acid 3 or retinoids) to increase cell turnover and help remove lesions, hormones or retinoid treatment to reduce sebum production, and antibiotics to reduce the bacterial infection1,6.

Antibiotics prescribed for acne can be topical or systemic. For systemic treatment, usually reserved for more severe acne, the oral tetracyclines (tetracycline 4, oxytetracycline, doxycycline, minocycline or lymecycline) are most commonly used1. Oral clindamycin 5 is effective but has adverse effects, while macrolides (erythromycin 6 and azithromycin), trimethoprim and the β-lactams ampicillin/amoxicillin/oxacillin 7 are discouraged due to concerns over growing resistance1,7. The use of systemic antibiotics, other than the tetracyclines and macrolides, is not recommended due to limited data supporting their use to treat acne7. Topical antibiotic options include tetracycline 4, clindamycin 5, and erythromycin 6, (see Fig. 1), sometimes in combination with benzoyl peroxide 1 and zinc acetate1. Dapsone (diaminodiphenyl sulfone) 8 (see Fig. 1), an anti-inflammatory agent with antimicrobial properties, has also been used. However, a number of other topical agents are proposed to act via multiple mechanisms, with the exfoliants benzoyl peroxide 1, azelaic acid 2, and salicylic acid 3 (see Fig. 1) commonly ascribed to also have antimicrobial activity. Surprisingly, there is little literature evidence of the extent of their antimicrobial activity, particularly under standardized broth microdilution assay conditions.

Figure 1
figure 1

Structures of antibiotics and anti-acne agents tested.

Full size image

The growing global crisis of antibiotic resistance is also reflected in antimicrobial acne therapy. Resistant strains of P. acnes have been reported in many countries (with resistance especially noted to topical erythromycin and clindamycin), and topical antibiotic use is associated with resistance in other commensal bacteria, such as Staphylococcus aureus8. The American Academy of Dermatology recommends that systemic antibiotic use should be limited to the shortest possible duration with re-evaluation at 3–4 months to minimize the development of bacterial resistance, and co-application of benzoyl peroxide (BP) to help reduce the development of resistance7. Topical therapy is strongly suggested to follow the discontinuation of systemic antibiotics as a maintenance regimen7. The European Evidence-Based Guideline for the Treatment of Acne has similar recommendations9.

The rise in antimicrobial resistance is accompanied by an increasing awareness of the role of the human microbiome in the ability of pathogenic species to establish an infection. Several recent genomic studies have specifically examined the human skin microbiome10,11,12,13,14,15,16,17, and even the subpopulation of P. acnes in the human skin microbiome18,19. These studies identify abundant populations of P. acnes and Staphylococcus spp. (especially S. epidermidis, but also S. aureus and S. hominis, and lower levels of S. warneri, S. saprophyticus, S. lugdunensis, S. haemolyticus and S. capitis). High levels of Corynebacterium, Streptococcus mitis and the fungus Malassezia globosa have also been identified, with community composition varying depending on the skin region and skin type (sebaceous, dry skin or wet skin)8,13. The top ten bacteria present in sebaceous sites are P. acnes, S. epidermidis, Corynebacterium tuberculostearicum, S. capitis, Corynebacterium simulans, S. mitis, S. hominis, Corynebacterium aurimucosum, Corynebacterium kroppenstedtii, and Corynebacterium amycolatum13. Lactobacillus, β-Proteobacteria and Flavobacteriales are also found in sebaceous sites, though usually are more common in ‘dry’ or ‘moist’ skin environments10. Altering the skin microbiome with topical antibiotic treatment can have significant effects on the cutaneous host defense20, and some skin bacteria (such as Micrococcus luteus) have been found to enhance S. aureus pathogenesis21. A new anti-acne tetracycline, sarecycline, has been designed as the first narrow-spectrum tetracycline-class antibiotic being developed for acne treatment, reducing collateral damage on the microbiome (though in this case used systemically, not topically)22.

It is important to know the relative effects of antimicrobial agents on human microbiota in order to understand their potential to foster resistance and alter the microbiome composition. To date, there has not been a comparative assessment of the antimicrobial activity of commonly used antibiotics and topical acne agents against a set of representative commensal skin bacteria, including those not directly associated with acne. We now report such a study against standardized accessible organisms from reference collections, testing both specific antibiotics used to treat acne (tetracycline, erythromycin, clindamycin, oxacillin, dapsone, along with control antibiotics vancomycin/colistin) and other acne agents reported to have antimicrobial activity (salicyclic acid, azelaic acid, benzoyl peroxide) (see Fig. 1). These are assessed against both sensitive and resistant bacterial strains, under anaerobic and aerobic conditions. In addition to some of the most common strains identified by microbiome studies, we also include several additional pathogenic bacteria that can be found on the skin and/or involved in skin infections, such as Streptococci (S. pyogenes and, less commonly S. pneumoniae23), Bacilli (B. subtilis, B. cereus and B. megaterium), Enterococci (E. faecium and E. faecalis), Micrococci (M. luteus and Kocuria rosea) and the Gram-negative bacteria Escherichia coli and Acinetobacter johnsonii24.

Results and Discussion

The antimicrobial activity of the antibiotics and anti-acne agents, tested under standard broth microdilution (BMD) conditions, are summarized in Tables 1–3. The topical acne therapeutics originally developed as specific antimicrobial agents (tetracycline, erythromicin, oxacillin, and clindamycin) generally showed potent activity under both anaerobic and aerobic conditions against a range of bacteria, though erythromycin, oxacillin and clindamycin lost substantial activity against resistant bacteria, such as MRSA (methicillin-resistant S. aureus) and MDR (multidrug-resistant) S. pneumoniae. Dapsone, an aniline sulfone first made in 1908 but discovered as an antimicrobial agent in 193725, was generally less effective than the other antibiotics but had widely varying activity that was dependant on the species (ranging from <2 µg/mL for S. pyogenes to >4100 µg/mL against a S. epidermidis strain, with the variable activity potentially partly due to poor solubility when diluting from stock solutions into media at high concentrations). Previous literature reports for broth Minimum Inhibitory Concentration (MIC) potency of tetracycline, erythromycin and clindamycin against P. acnes also showed a wide variation against 16 strains, with activity ranges of ≤0.06 to 31, ≤0.25 to >1000, and ≤0.125 to >500 µg/mL respectively for the three antibiotics26, with results from the current study generally fitting into these ranges.

Table 1 Minimum Inhibitory Concentrations measured under anaerobic conditions, µg/mL*.

Full size table

Table 2 Minimum Inhibitory Concentrations against Gram-Positive bacteria measured under aerobic conditions, µg/mL.

Full size table

Table 3 Minimum Inhibitory Concentrations against Gram-Negative bacteria measured under aerobic conditions, µg/mL.

Full size table

In sharp contrast, the ‘non-antibiotic’ acne agents (salicylic acid, azelaic acid and benzoyl peroxide) that are believed to help treat acne by multiple mechanisms, including bacterial inhibition, had substantially lower, but measurable, activity, compared to true antibiotics. Their potency, generally ranging from 2000-64,000 µg/mL, was approximately 1000-fold less active than the designated antibiotics. However, their activity was maintained against all of the resistant bacteria tested, including highly resistant strains of S. aureus, S. epidermidis, and S. pneumoniae where almost all the antibiotics failed.

Previous reports of the direct antimicrobial activity of salicyclic acid are limited, with disc diffusion measurements of activity in 1962 versus E. coli, Aerobacter aerogenes, Leuconostoc mesenteroides P-60, S. aureus, ‘Streptococcus faecalis’ [sic] and five fungi27. In 2014 the MIC and Minimum Bactericidal Concentration (MBC) of salicylic acid and other phytochemicals were assessed against E. coli (MIC = 3200 µg/mL) and S. aureus (MIC = 1600 µg/mL)28, compared to MIC = 16000 µg/mL and 32000–64000 µg/mL, respectively in this study. A 2007 study showed 5 mM salicylate (approx. 700 µg/mL) halted growth of SH1000 S. aureus after 5h29, though the same concentration only slightly slowed the growth of E. coli GC446830. A 2011 article on new antimicrobial formulations compared their activity against P. acne to salicyclic acid, with MIC90 for salicyclic acid of 1000 µg/mL26, compared to 8000 µg/mL in this study. A review of the effects of salicylate on bacteria was published in 200031, which summarized research showing that, at concentrations that do not substantially affect bacterial growth, salicylate can: (a) induce antibiotic resistance, (b) reduce resistance to some antibiotics; and (c) affect production of bacterial virulence factors. More recent studies have supported the reduction in susceptibility of organisms such as S. aureus29 or Salmonella enterica serovar Typhimurium32 to common antibiotics or antiseptics in the presence of salicylate. Further studies are warranted to see if topical use of salicylate for acne reduces the effectiveness of topical acne antibiotics.

The antimicrobial potential of azelaic acid has been more thoroughly studied than that of salicyclic acid, with a review in 199333. The first observation that it exerted a bacteriostatic effect on aerobic and anaerobic bacteria (including Propionibacterium) appeared as a comment in a 1983 clinical report34. A clinical trial noted a 224-fold reduction in the population of Micrococcaceae and 30-fold decrease in the density of Propionibacterium sp. on the skin after application of 20% azelaic acid cream (compared to no effect from tetracycline)35. Another report measured MIC in broth at pH 6.0 against S. epidermidis, S. capitis, and S. hominis (125 mM, approximately 23,500 µg/mL, similar to our values of 8000-16,000 µg/mL), P. acne and P. granulosum (>250 mM ≈ >47,000 µg/mL, versus 8000–16,000 µg/mL in this study), Propionibacterium avidum (31 mM ≈ 5900 µg/mL) and Pityrosporum ovale (now known as Malassezia ovale) (250 mM ≈ 47,000 µg/mL)36. In 1991 concentrations of 500 mM (≈ 94,000 µg/mL) were reported to exert bactericidal activity against P. acne in vitro at pH 6.0, with activity enhanced by lowering the pH to 5.6 but little activity at pH 7.037. A 1992 report compared the in vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against MRSA38. Against 80 MRSA strains, the MIC50 and MIC90 of azelaic acid, measured by agar dilution, were 850 µg/mL and 1150 µg/mL respectively (no pH mentioned), with a range of 600–1200 µg/mL38, around 10-fold less than our BMD MIC values (8000–16,000 µg/mL). The corresponding MBC values were 1800 µg/mL and 3500 µg/mL respectively. Azelaic acid was slowly bactericidal at 2500 µg/mL, with around 3-log reduction from a starting inoculum of 106 cfu after 24 h; a resistance mutation rate of <1 × 10−9 was observed38. The authors of the 1993 review also noted in the review that they had conducted an in vitro experiment to assess the development of resistance in P. acnes or S. epidermidis over 53 days exposed to 2–4 mM (400–800 µg/mL) azelaic acid, with no changes in MIC detected33.

Finally, benzoyl peroxide has long been known to have antimicrobial properties, with speculation of antiseptic action in the 1920’s and treatment of acne/skin lesions in the 1930’s39. The history of its application for the treatment of acne was reviewed in 198740 and 200939. Survival curves of S. epidermidis, S. capitis, S. hominis, P. acne, P. granulosum, P. avidum and P. ovale have been measured in the presence of 10−2 – 10−4 w/v% benzoyl peroxide, with bacteria showing varying sensitivity but all killed at the higher concentrations41. Another study looked at 10 sensitive and 10 erythromycin resistant strains of P. acne, P. granulosum, P avidum, and 10 sensitive and 10 erythromycin resistant strains of S. epidermidis, with benzoyl peroxide agar dilution MIC of 64–128 µg/mL and 512 µg/mL respectively42 (compared to BMD MIC of 2048 µg/mL in this study; their benzoyl peroxide parent solution had 5% w/w benzoyl peroxide but also contained carbomer 940, 14% alcohol, sodium hydroxide, dioctylsodium sulphosuccinate and fragrance). In 1989 MICs against nine P. acne strains were reported to be between 100–800 µg/mL43 using a modified broth with added 2%Tween and glycerol to improve benzoyl peroxide solubility, a 2 × 104 innoculum, and four day incubation (compared to 2048 µg/mL in this study with BHI broth, 5 × 105 innoculum, and 48 h incubation). It was also not clear what form of benzoyl peroxide was used in the 1989 report, as it was “obtained from commercial products” so likely contained other components. More potent BMD MICs of 62.5, 15.6 and >100 µg/mL were reported against P. acne, S. aureus and S. epidermidis in 2009, again employing different assay conditions from our study that included varied incubation times (72, 24 and 48 h respectively)44. A comparison of the activity of new antimicrobial formulations against P. acne used benzoyl peroxide as a standard, with MIC90 for benzoyl peroxide of 50 µg/mL26 (compared to 2048 µg/mL determined in this study). A 2016 study assessed the activity of benzoyl peroxide against 44 clinical isolates of P. acne using the Decker modified broth, with MIC50 = 128 µg/mL and MIC90 = 256 µg/mL. MBCs were similar to MICs, and a time kill assay showed 5-log reduction in cfu after 1 h at two-fold MIC45.

In summary, this study clearly demonstrates that acne agents used primarily for their skin exfoliating properties do indeed have modest, but widespread, antimicrobial activity against a range of skin-associated bacteria, at least when tested in broth microdilution assays. Many skin-related bacteria can form biofilms, which are notoriously more resistant to antimicrobial therapies than vegetative bacteria. The exfoliant topical agents are generally applied at concentrations up to 20-fold higher than topical antibiotics (though in some cases at equivalent concentrations), so they are likely to exert substantial antimicrobial effects despite their reduced antimicrobial potency. Benzoyl peroxide is used as 2.5–10% solutions in gel, cream, lotions or liquid46, azelaic acid as 15–20% lotions46, and salicylic acid in a range of concentrations (with 0.5–2% commonly used, but up to 10% employed for acne treatments: 2% is the maximum strength allowed in over-the-counter acne products in the United States). Clindamycin, erythromycin and tetracycline topical treatments are generally in the 1–4% range43,44,45,46,47, with dapsone used in a 5% gel46. The retention of high levels of antimicrobial activity by salicylic acid, azelaic acid and benzoyl peroxide against antibiotic-resistant strains of bacteria suggests that these treatments could be useful alternatives to antibiotic-based therapies in the case of resistant bacteria, and should be further explored as preferred alternatives to prescribed antibiotics to help reduce the development of resistance.

Methods

Compound preparation

Stock solutions of compounds were prepared in different solvents at different concentrations, depending on solubility and expected activity range, as presented in Table 4.

Table 4 Compounds assayed.

Full size table

Minimum Inhibitory Concentration (MIC) determinations

Bacterial strains were purchased from the American Type Culture Collection (ATCC) or Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) (see Table 5).

Table 5 Bacterial strains assayed.

Full size table

Standard aerobic MIC Assay

The compounds along with standard antibiotics were serially diluted with Mueller Hinton broth (MHB) (Bacto laboratories, Cat. No 211443) two-fold across the wells of 96-well standard Polystyrene plates (Corning 3370). For antibiotics not initially dissolved in water, the highest solvent (DMSO) concentration in the final assay solution was 2%. Solvent controls have shown that this concentration does not interfere with bacteria growth. All bacteria strains were cultured in MHB at 37 °C overnight. A sample of each culture was then diluted 40-fold in fresh MHB and incubated at 37 °C for a further 2–3 h. The resultant mid-log phase cultures were diluted in MHB and added to each well of the compound-containing 96-well plates to give a final cell density of 5 × 105 CFU/mL. All the plates were covered and incubated at 37 °C for 24 h. MICs were determined as the lowest concentration showing no visible growth by eye. Assays were conducted in duplicate, with two independent assays (n = 4).

Standard anaerobic MIC Assay

The MIC assay for anaerobic growth conditions was performed to the same procedure as the standard aerobic MIC assay described above with the following exceptions:

All steps were performed in a COY type B anaerobic chamber with the anaerobic atmosphere controlled by the introduction of 10%CO2/5% H2 in N2CoA gas mix, catalyst Stak-Pak and O2-H2 gas analyzer, with H2 levels kept at ~2% for the duration of the assay. Brain Heart Infusion (BHI) (OXOID CM1135B) media with 1% cysteine to further promote an anaerobic environment was used in replacement of MHB, and this broth was incubated in the anaerobic chamber for 24 h prior to use to allow sufficient atmosphere exchange. All the plates were covered and incubated at 37 °C for 48 h. MICs were determined as the lowest concentration showing no visible growth by eye.

References

  1. Williams, H. C., Dellavalle, R. P. & Garner, S. Acne vulgaris. Lancet 379, 361–372 (2012).

    Article  Google Scholar 

  2. Hay, R. J. et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J. Invest. Dermatol. 134, 1527–1534 (2014).

    Article  CAS  Google Scholar 

  3. Alexeyev, O. A. et al. Why we continue to use the name Propionibacterium acnes. Brit. J. Dermatol. 179, 1227–1227 (2018).

    Article  CAS  Google Scholar 

  4. Leyden, J. J. New understandings of the pathogenesis of acne. J. Am. Acad. Dermatol. 32, S15–25 (1995).

    Article  CAS  Google Scholar 

  5. Dawson, A. L. & Dellavalle, R. P. Acne vulgaris. BMJ 346, f2634 (2013).

    Article  Google Scholar 

  6. Millikan, L. E. Acne therapy: old wine in new vessels – the promise (and pitfalls) of new drug deliveries and regimens. Exp. Rev. Dermatol. 4, 191–194 (2009).

    Article  CAS  Google Scholar 

  7. Zaenglein, A. L. et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 74, 945–973 (2016).

    Article  Google Scholar 

  8. Adler, B. L., Kornmehl, H. & Armstrong, A. W. Antibiotic resistance in acne treatment. J. Am. Acad. Dermatol. 153, 810–811 (2017).

    Google Scholar 

  9. Nast, A. et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J. Eur. Acad. Dermatol. Venereol. 30, 1261–1268 (2016).

    Article  CAS  Google Scholar 

  10. Grice, E. A. et al. Topographical and Temporal Diversity of the Human Skin Microbiome. Science 324, 1190–1192 (2009).

    Article  ADS  CAS  Google Scholar 

  11. Brandwein, M., Steinberg, D. & Meshner, S. Microbial biofilms and the human skin microbiome. npg Biofilms and Microbiomes 2, 3 (2016).

    Article  Google Scholar 

  12. Ross, A. A., Müller, K. M., Weese, J. S. & Neufeld, J. D. Comprehensive skin microbiome analysis reveals the uniqueness of human skin and evidence for phylosymbiosis within the class. Mammalia. Proc. Nat. Acad. Sci. 115, E5786–E5795 (2018).

    Article  CAS  Google Scholar 

  13. Byrd, A. L., Belkaid, Y. & Segre, J. A. The human skin microbiome. Nature Rev. Microbiol. 16, 143–155 (2018).

    Article  CAS  Google Scholar 

  14. Meisel, J. S. et al. Skin microbiome surveys are strongly influenced by experimental design. J. Invest. Dermatol. 136, 947–956 (2016).

    Article  CAS  Google Scholar 

  15. Oh, J., Byrd, A. L., Park, M., Kong, H. H. & Segre, J. A. Temporal Stability of the Human Skin Microbiome. Cell 165, 854–866 (2016).

    Article  CAS  Google Scholar 

  16. Oh, J. et al. Biogeography and individuality shape function in the human skin metagenome. Nature 514, 59–64 (2014).

    Article  CAS  Google Scholar 

  17. Schloss, P. D. An integrated view of the skin microbiome. Nature 514, 44–45 (2014).

    Article  ADS  CAS  Google Scholar 

  18. Fitz-Gibbon, S. et al. Propionibacterium acnes Strain Populations in the Human Skin Microbiome Associated with Acne. J. Invest. Dermatol. 133, 2152–2160 (2013).

    Article  CAS  Google Scholar 

  19. Eady, E. A. & Layton, A. M. A Distinct Acne Microbiome: Fact or Fiction? J. Invest. Dermatol. 133, 2294–2295 (2013).

    Article  CAS  Google Scholar 

  20. SanMiguel, A. J., Meisel, J. S., Horwinski, J., Zheng, Q. & Grice, E. A. Topical antimicrobial treatments can elicit shifts to resident skin bacterial communities and reduce colonization by Staphylococcus aureus competitors. Antimicrob. Agents Chemother. 61, e00774–00717 (2017).

    Article  CAS  Google Scholar 

  21. Boldock, E. et al. Human skin commensals augment Staphylococcus aureus pathogenesis. Nature Microbiol. 3, 881–890 (2018).

    Article  CAS  Google Scholar 

  22. Zhanel, G., Critchley, I., Lin, L.-Y. & Alvandi, N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob. Agents Chemother. 63, e01297–01218 (2019).

    CAS  PubMed  Google Scholar 

  23. Garcia-Lechuz, J. M. et al. Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness. Eur. J. Clin. Microbiol. Infect. Dis. 26, 247–253 (2007).

    Article  CAS  Google Scholar 

  24. Seifert, H. et al. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J. Clin. Microbiol. 35, 2819–2825 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Wozel, G. & Blasum, C. Dapsone in dermatology and beyond. Arch. Dermatol. Res. 306, 103–124 (2014).

    Article  CAS  Google Scholar 

  26. Pannu, J. et al. In Vitro Antibacterial Activity of NB-003 against Propionibacterium acnes. Antimicrob. Agents Chemother. 55, 4211–4217 (2011).

    Article  CAS  Google Scholar 

  27. Gershon, H. & Parmegiani, R. Antimicrobial Activity of 8-Quinolinols, Salicylic Acids, Hydroxynaphthoic Acids, and Salts of Selected Quinolinols with Selected Hydroxy-Acids. Applied Microbiol. 10, 348–353 (1962).

    CAS  Google Scholar 

  28. Monte, J., Abreu, A., Borges, A., Simões, L. & Simões, M. Antimicrobial Activity of Selected Phytochemicals against Escherichia coli and Staphylococcus aureus and their Biofilms. Pathogens 3, 473–498 (2014).

    Article  CAS  Google Scholar 

  29. Riordan, J. T. et al. Response of Staphylococcus aureus to Salicylate Challenge. J. Bacteriol. 189, 220–227 (2007).

    Article  CAS  Google Scholar 

  30. Pomposiello, P. J., Bennik, M. H. J. & Demple, B. Genome-Wide Transcriptional Profiling of the Escherichia coli Responses to Superoxide Stress and Sodium Salicylate. J. Bacteriol. 183, 3890–3902 (2001).

    Article  CAS  Google Scholar 

  31. Price, C. T. D., Lee, I. R. & Gustafson, J. E. The effects of salicylate on bacteria. Int. J. Biochem. Cell Biol. 32, 1029–1043 (2000).

    Article  CAS  Google Scholar 

  32. Hartog, E., Menashe, O., Kler, E. & Yaron, S. Salicylate reduces the antimicrobial activity of ciprofloxacin against extracellular Salmonella enterica serovar Typhimurium, but not against Salmonella in macrophages. J. Antimicrob. Chemother. 65, 888–896 (2010).

    Article  CAS  Google Scholar 

  33. Holland, K. & Bojar, R. Antimicrobial effects of azelaic acid. J. Dermatol. Treat. 4, S8–S11 (1993).

    Article  Google Scholar 

  34. Nazzaro-Porro, M. et al. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Brit. J. Dermatol. 109, 45–48 (1983).

    Article  CAS  Google Scholar 

  35. Bladon, P. T. et al. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Brit. J. Dermatol. 114, 493–499 (1986).

    Article  CAS  Google Scholar 

  36. Leeming, J. P., Holland, K. T. & Bojar, R. A. The in vitro antimicrobial effect of azelaic acid. Brit. J. Dermatol. 115, 551–556 (1986).

    Article  CAS  Google Scholar 

  37. Bojar, R. A., Holland, K. T. & Cunliffe, W. J. The in-vitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37. J. Antimicrob. Chemother. 28, 843–853 (1991).

    Article  CAS  Google Scholar 

  38. Maple, P. A. C., Hamilton-Miller, J. M. T. & Brumfitt, W. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 29, 661–668 (1992).

    Article  CAS  Google Scholar 

  39. Sagransky, M., Yentzer, B. A. & Feldman, S. R. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Exp. Opin. Pharmacother. 10, 2555–2562 (2009).

    Article  CAS  Google Scholar 

  40. Cunliffe, W. J. Evolution of a strategy for the treatment of acne. J. Am. Acad. Dermatol. 16, 591–599 (1987).

    Article  CAS  Google Scholar 

  41. Cove, J. H. & Holland, K. T. The effect of benzoyl peroxide on cutaneous micro-organisms in vitro. J. Applied Bacteriol. 54, 379–382 (1983).

    Article  CAS  Google Scholar 

  42. Eady, E. A., Farmery, M. R., Ross, J. I., Cove, J. H. & Cunliffe, W. J. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Brit. J. Dermatol. 131, 331–336 (1994).

    Article  CAS  Google Scholar 

  43. Decker, L. C., Deuel, D. M. & Sedlock, D. M. Role of lipids in augmenting the antibacterial activity of benzoyl peroxide against Propionibacterium acnes. Antimicrob. Agents Chemother. 33, 326–330 (1989).

    Article  CAS  Google Scholar 

  44. Nakatsuji, T. et al. Antimicrobial Property of Lauric Acid Against Propionibacterium Acnes: Its Therapeutic Potential for Inflammatory Acne Vulgaris. J. Invest. Dermatol. 129, 2480–2488 (2009).

    Article  CAS  Google Scholar 

  45. Okamoto, K. et al. In vitro antimicrobial activity of benzoyl peroxide against Propionibacterium acnes assessed by a novel susceptibility testing method. J. Infect. Chemother. 22, 426–429 (2016).

    Article  CAS  Google Scholar 

  46. Simonart, T. Newer Approaches to the Treatment of Acne Vulgaris. Amer. J. Clin. Dermatol. 13, 357–364 (2012).

    Article  Google Scholar 

  47. American Academy of Dermatology, Practice Management Center, Topical Therapies: Recommendations, www.aad.org/practicecenter/quality/clinical-guidelines/acne/topical-therapies (accessed Aug 2019).

Download references

Acknowledgements

This research was supported financially by funding from Mimetica Pty Ltd. MATB, AGE and SR, and AK were supported in part by Wellcome Trust Seeding Drug Discovery Award (094977/Z/10/Z) and Wellcome Trust Strategic Award 104797/Z/14/Z. MAC is a former NHMRC Australian Fellow (AF511105) and current NHMRC Principal Research Fellow (APP1059354) who holds a fractional Professorial Research Fellow appointment at the University of Queensland with his remaining time as CEO of Inflazome Ltd. a company headquartered in Dublin, Ireland that is developing drugs to address clinical unmet needs in inflammatory disease by targeting the inflammasome. Strains S. epidermidis Strain NR-45891 (NRS60) and S. aureus NR-46410 (VRS1) were provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH. S. aureus NRS1 (Mu50, ATCC 700699) was originally provided by NARSA, now available from American Type Culture Collection (ATCC), all other ATCC strains were acquired directly from ATCC.

Author information

Authors and Affiliations

  1. Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, 4072, Australia

    Mark A. T. Blaskovich, Alysha G. Elliott, Angela M. Kavanagh, Soumya Ramu & Matthew A. Cooper

Contributions

M.A.T.B. conceptualized the study, acquired specific funding for the project, and wrote the original draft of the manuscript, with all authors contributing to manuscript review and editing. A.G.E., A.M.K. and S.R. conducted the investigations and analysis, with A.G.E. providing project administration. M.A.C. acquired general support funding and provided supervision.

Corresponding author

Correspondence to Mark A. T. Blaskovich.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blaskovich, M.A.T., Elliott, A.G., Kavanagh, A.M. et al. In vitro Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria. Sci Rep 9, 14658 (2019). https://doi.org/10.1038/s41598-019-50746-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41598-019-50746-4

RELATED ARTICLESMORE FROM AUTHOR

LEAVE A REPLY

Please enter your comment!
Please enter your name here